Sperm count in men from North America, Europe, Australia and New Zealand declined by 50-60% between 1973 and 2011, according to a new study from the Hebrew University of Jerusalem. Surprisingly, the study, which analysed data on the sperm counts of 42,935 men, found no decline in sperm counts in men from Asia, Africa and South America, although there was limited data from these areas.
Overall, this is a very disturbing report. There has been a longstanding debate among scientists as to whether sperm counts have decreased or not. But what’s different about this study is the quality of the analysis. It was done in a systematic manner, accounting for several of the problems that had affected previous studies, such as the method used to count sperm and comparing studies performed sometimes decades apart. As such, most experts agree that the data presented is of a high quality and that the conclusions, although alarming, are reliable.
So what is going on? There has been concern for a number of years about an increase in abnormalities in male reproductive health, such as testicular cancer. The decline is sperm counts is consistent with these increases and this adds weight to the concept that male reproductive health is under attack and is declining rapidly.
In fact, if the data on sperm counts is extrapolated to its logical conclusion, men will have little or no reproductive capacity from 2060 onwards. The most rational explanation for the decline in male reproductive health is the changes in the environment. Current research suggests that the male foetus is particularly susceptible to exposure to pollutants and so changes that occur early in foetal life can have a very significant effect on the adult.
What can be done?
The simple answer is that we need much more research to find out why this decline in sperm count is happening. We cannot be complacent about the potential negative effect on fertility and must now urgently rally to substantially increase the research effort into male reproductive health.
Also, although the prevailing evidence shows a decline in reproductive health, not all studies show this; there are some geographical differences. It will be critical to determine what the key differences between geographical regions are – such as genetic differences and exposure to specific pollutants – so we can then examine treatment strategies to limit these negative effects.
If it’s the foetus that is mainly affected, what can the adult man do? Even in adults, exposure to chemicals, such as bisphenol A, which are thought to affect fertility, can have a negative effect, so men should limit their exposure to toxic chemicals. This includes stopping cigarette smoking. Also, a healthy lifestyle is very important as there is a known link between obesity and reduced sperm count.
Chris Barratt receives funding from MRC NHS and Bill and Melinda Gates Foundation Editor In Chief MHR


Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 



